Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient

  • Saxena, Abhishek
  • Stevens, Jo|||0000-0001-5737-7325
  • Cetin, Hakan
  • Koneczny, Inga
  • Webster, Richard
  • Lazaridis, Konstantinos
  • Tzartos, Socrates
  • Vrolix, Kathleen
  • Nogales, Gisela|||0000-0002-7414-212X
  • Machiels, Barbie
  • Molenaar, Peter C.
  • Damoiseaux, Jan
  • De Baets, Marc H.
  • Simon-Keller, Katja|||0000-0003-2340-8765
  • Marx, Alexander
  • Vincent, Angela|||0000-0003-2395-8695
  • Losen, Mario|||0000-0002-9761-0002
  • Martinez-Martinez, Pilar
We report here the sequence and functional characterization of a recombinantly expressed., autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high degree of somatic mutations as well as a 6 amino acid insertion within the VHCDR2. The recombinant mAb 131 is specific for the γ-subunit of the fetal AChR to which it bound with sub-nanomolar apparent affinity, and detected the presence of fetal AChR on a number of rhabdomyosarcoma cell lines. Mab 131 blocked one of the two α-bungarotoxin binding sites on the fetal AChR, and partially blocked the binding of an antibody (mAb 637) to the α-subunit of the AChR, suggesting that both antibodies bind at or near one ACh binding site at the α/γ subunit interface. However, mAb 131 did not reduce fetal AChR ion channel currents in electrophysiological experiments. These results indicate that mAb 131, although generated from an MG patient, is unlikely to be pathogenic and may make it a potentially useful reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita which can be caused by fetal-specific AChR-blocking autoantibodies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease

  • Rodríguez-Gómez, Irene|||0000-0002-1622-7109
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Díez Bermejo, Jorge
  • Munguía-Izquierdo, Diego|||0000-0001-7817-747X
  • Alegre, Luis M.|||0000-0002-4502-9275
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Ara, Ignacio|||0000-0002-2854-6684
McArdle disease (glycogenosis-V) is associated with exercise intolerance, however, how it affects an important marker of cardiometabolic health as it is adiposity remains unknown. We evaluated the association between physical activity (PA) and adiposity in patients with McArdle disease. We assessed 199 adults of both sexes (51 McArdle patients (36 ± 11 years) and 148 healthy controls (35 ± 10 years)). Body fat (BF) was determined using dual-energy X-ray absorptiometry (DXA) method and each patient's PA was assessed with the International PA Questionnaire (IPAQ). Although body mass index values did not differ between patients and controls, McArdle patients had significantly higher values of BF in all body regions (p < 0.05) and higher risk of suffering obesity (odds ratio (OR): 2.54, 95% confidence interval (95% CI): 1.32-4.88). Male patients had higher BF and obesity risk (OR: 3.69, 95% CI: 1.46-9.34) than their sex-matched controls, but no differences were found within the female sex (p < 0.05). In turn, active female patients had lower trunk BF than their inactive peers (p < 0.05). Males with McArdle seem to have adiposity problems and a higher risk of developing obesity than people without the condition, while female patients show similar or even better levels in the trunk region with an active lifestyle. Therefore, special attention should be given to decrease adiposity and reduce obesity risk in males with McArdle disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Need for Establishing a Universal CTG Sizing Method in Myotonic Dystrophy Type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Linares-Pardo, Ian
  • Koehorst, Emma
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Magaña, Jonathan J.|||0000-0003-4399-4618
  • Murillo-Melo, Nadia M.
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Monckton, Darren G.|||0000-0002-8298-8264
  • Cumming, Sarah A.|||0000-0002-0201-3660
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
The number of cytosine-thymine-guanine (CTG) repeats ('CTG expansion size') in the 3'untranslated region (UTR) region of the dystrophia myotonica -protein kinase (DMPK) gene is a hallmark of myotonic dystrophy type 1 (DM1), which has been related to age of disease onset and clinical severity. However, accurate determination of CTG expansion size is challenging due to its characteristic instability. We compared five different approaches (heat pulse extension polymerase chain reaction [PCR], long PCR-Southern blot [with three different primers sets-1, 2 and 3] and small pool [SP]-PCR) to estimate CTG expansion size in the progenitor allele as well as the most abundant CTG expansion size, in 15 patients with DM1. Our results indicated variability between the methods (although we found no overall differences between long PCR 1 and 2 and SP-PCR, respectively). While keeping in mind the limited sample size of our patient cohort, SP-PCR appeared as the most suitable technique, with an inverse significant correlation found between CTG expansion size of the progenitor allele, as determined by this method, and age of disease onset (r = -0.734, p = 0.016). Yet, in light of the variability of the results obtained with the different methods, we propose that an international agreement is needed to determine which is the most suitable method for assessing CTG expansion size in DM1
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I

  • López-Martínez, Andrea|||0000-0003-4711-7495
  • Soblechero-Martín, Patricia
  • de-la-Puente-Ovejero, Laura|||0000-0002-0835-7069
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
Myotonic dystrophy type I (DM1) is the most common form of adult muscular dystrophy, caused by expansion of a CTG triplet repeat in the 3' untranslated region (3'UTR) of the myotonic dystrophy protein kinase (DMPK) gene. The pathological CTG repeats result in protein trapping by expanded transcripts, a decreased DMPK translation and the disruption of the chromatin structure, affecting neighboring genes expression. The muscleblind-like (MBNL) and CUG-BP and ETR-3-like factors (CELF) are two families of tissue-specific regulators of developmentally programmed alternative splicing that act as antagonist regulators of several pre-mRNA targets, including troponin 2 (TNNT2), insulin receptor (INSR), chloride channel 1 (CLCN1) and MBNL2. Sequestration of MBNL proteins and up-regulation of CELF1 are key to DM1 pathology, inducing a spliceopathy that leads to a developmental remodelling of the transcriptome due to an adult-to-foetal splicing switch, which results in the loss of cell function and viability. Moreover, recent studies indicate that additional pathogenic mechanisms may also contribute to disease pathology, including a misregulation of cellular mRNA translation, localization and stability. This review focuses on the cause and effects of MBNL and CELF1 deregulation in DM1, describing the molecular mechanisms underlying alternative splicing misregulation for a deeper understanding of DM1 complexity. To contribute to this analysis, we have prepared a comprehensive list of transcript alterations involved in DM1 pathogenesis, as well as other deregulated mRNA processing pathways implications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I

  • Koehorst, Emma
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dominant muscle dystrophy in adults, with an estimated prevalence of 1:8000. DM1 symptoms include muscle weakness, myotonia, respiratory failure, cardiac conduction defects, cataracts, and endocrine disturbances. Patients display heterogeneity in both age of onset and disease manifestation. No treatment or cure currently exists for DM1, which shows the necessity for a biomarker that can predict disease progression, providing the opportunity to implement preventative measures before symptoms arise. In the past two decades, extensive research has been conducted in the miRNA expression profiles of DM1 patients and their biomarker potential. Here we review the current state of the field with a tissue-specific focus, given the multi-systemic nature of DM1 and the intracellular signaling role of miRNAs.